MedTrace Logo

Cognitive Detection of Preclinical AD: Validation Using Biomarkers

NCT02616679 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2021-01-15

No results posted yet for this study

Summary

The current study aims to validate several novel cognitive tasks expected to be sensitive to brain impairment in specific anatomic regions affected in preclinical Alzheimer's disease(pAD). The tasks are validated in 60 cognitively and clinically normal participants ages 60 - 85, inclusive, against reasonably well-established biomarkers of Alzheimer's disease, including 1) simultaneous positron emission tomography (PET) \[18F\]Flutemetamol amyloid and CT imaging and 2) to the extent data is available from other studies, participants' brain MRI and cerebral spinal fluid (CSF) amyloid and tau.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Martin Sadowski, PhD · NYU Langone Medical Center

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-05
Primary Completion
2020-08-12
Completion
2020-08-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02616679 on ClinicalTrials.gov